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Enamel matrix derivative (EMD) is widely considered useful to promote tissue 
regeneration during periodontal treatment. It has been reported that the main constituent 
of EMD is amelogenin and that the BMP–like and TGF–β–like activity of EMD 
promotes osteogenesis. However, it remains unclear whether those activities are 
dependent on amelogenin or another growth factor contained in EMD. We performed 
two–dimensional SDS–PAGE analysis of EMD, as well as Western blot analyses using 
anti–amelogenin, anti–BMP2/4, and anti–TGF–β1 antibodies, and amino acid 
sequencing. Our results revealed that a large number of splicing forms of amelogenin, 
BMP2/4, and other unknown molecules were involved in EMD, though TGF–β1 was 
not. In addition, we have evaluated intracellular signaling of ERK1/2 and Smad1/5/8, 
binding potential and alkaline phosphatase activity and have explored the potential 
regulatory relationship between amelogenin and BMP. Amelogenin bound to BMP2 as 
well as heparin/heparan sulfate. Thus, it was suggested that BMP2/4 carried over in 
EMD during processing promote binding activity and phosphorylate Smad1/5/8 in 
osteoblasts. On the other hand, amelogenin did not phosphorylate Smad1/5/8, but rather 
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ERK1/2. Further, high density amelogenin reduced the inhibition of alkaline 
phosphatase activity by noggin, though amelogenin did not have antagonistic properties 
against BMP. Together with the above findings, our findings suggest that the BMP2/4 
contaminated during the purification process of EMD because of the avidity of 
amelogenin plays an important role in signaling pathway of calcification. 
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Enamel matrix derivative (EMD) is derived from developing porcine teeth. A recent 
clinical review reported that EMD promotes both cementogenesis [1] and osteogenesis 
[2], while it has also been shown that EMD has bone morphogenetic protein (BMP) and 
transforming growth factor–β (TGF–β) activities [3, 4], while in vitro experiments 
demonstrated that it stimulates osteoblast proliferation and differentiation [5, 6]. EMD 
consists of amelogenin at nearly 90%, along with other enamel matrix proteins, such as 
enamelin, tuftelin, amelin, and ameloblastin [7, 8]. Amelogenin is expressed in a 
tissue–specific manner by ameloblast, of which the origin is ectoderm. Immature 
enamel contains a complex mixture of amelogenin polypeptides, primarily due to the 
combined effects of alternative splicing [9, 10]. Numerous mutations have been found 
in the genes encoding amelogenin in patients with amelogenesis imperfecta, the most 
common genetic disorder affecting enamel [11, 12]. Thus, it is thought that amelogenin 
plays a crucial role in enamel formation. On the other hand, though there is no known 
clinical report showing that amelogenin causes bone diseases, in vitro experiment 
results have provided some indications of its function in bone formation. For example, 
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leucine–rich amelogenin peptide (LRAP) is expressed in cementoblasts/periodontal 
ligament cells and regulates osteoclastogenesis [13], and was shown to down–regulate 
osteocalcin, a marker of bone turnover [14, 15]. In another study, amelogenin decreased 
the levels of RANKL, M–CSF, and fibronectin in osteoblasts [16]. However, it remains 
unknown whether the activity of amelogenin is equal to that of EMD in bone formation. 
In the present study, we investigated EMD using two–dimensional SDS–PAGE assays 
and Western blot analyses to determine the differences between EMD and amelogenin. 
Our findings revealed that BMP2/4 contaminated EMD during processing. We also 
examined ERK1/2 and Smad1/5/8 intracellular signaling, the binding properties of 
amelogenin for BMP2, heparin, and heparan sulfate, and the alteration of alkaline 
phosphatase activity by amelogenin during calcification, to determine the relationship 
between amelogenin and BMP. 
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Materials and methods 
 
 
Two–dimensional SDS–PAGE (2–D PAGE) and Western blot analyses 
 
The commercial enamel matrix derivative Emdogain®, extracted from developing 
porcine teeth, was purchased from Seikagaku–kougyou Corporation (Tokyo, Japan) and 
used in the experiments. Approximately 5 μg of protein was added to 155 μL of sample 
rehydration buffer and absorbed overnight onto 7–cm nonlinear immobilized pH 
gradient (IPG, pH 3–10) ZOOM strips (Invitrogen Corp., Carlsbad, CA). Isoelectric 
focusing was carried out using a ZOOM® IPG Runner system (Invitrogen) and a 
MAJOR SCIENCE MP–3500/250P power supply (Invitrogen) with the following 
voltage step protocol: 200 V for 15 minutes, 450 V for 15 minutes, 750 V for 15 
minutes, and 2000 V for 60 minutes. For the second dimension, focused IPG strips were 
equilibrated in NuPAGE® LDS sample buffer (Invitrogen) in the presence of NuPAGE® 
Sample Reducing Agent (Invitrogen) for 15 minutes, and then further incubated in LDS 
sample buffer in the presence of 125 mM iodoacetamide for 15 minutes. Next, the strips 
were placed on NuPAGE® 4–12% Bis–Tris gels (Invitrogen) and embedded in 0.5% 
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agarose (wt/vol).  
Coomassie brilliant blue (CBB) staining of the gels was performed using 
SimplyBlue SafeStainTM (Invitrogen). For immunoblotting, proteins were separated 
using 2–D PAGE and transferred to 0.2–μm polyvinylidene fluoride (PVDF) 
membranes (Invitrogen) for 30 minutes at a constant 200 V. After blocking with 5% 
nonfat dry milk and 0.2% Tween 20 in Tris borate saline (TBS) at 4˚C overnight, the 
membranes were incubated with rabbit anti–amelogenin (anti–AMEL; HOKUDO CO., 
LTD, Sapporo, Japan), goat anti–BMP2/4 (R&D systems, Minneapolis, MN), or mouse 
anti–human TGF–β1 (R&D systems) antibodies in TBS containing 1% bovine serum 
albumin for 1 hour at room temperature. The antibodies were used at a dilution of 
1:1000. The membranes were washed 5 times with TBS containing 0.2% Tween and 
then incubated with secondary antibodies at a dilution of 1:3000 in TBS with 1% bovine 
serum albumin for 1 hour at room temperature. The membranes were then washed 5 
times with TBS and signals were detected using an ECL kit (Amersham Pharmacia 
Biosciences, Uppsala, Sweden).  
 
 
Analyses of 2–D gel and Western blotting results 
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CBB–stained gels were scanned at 500 dpi and the images analyzed using 
Progenesis PG200 Software (Nonlinear Dynamics, Newcastle upon Tyne, UK) to 
determine the number, molecular weight, isoelectric point, and relative volume ratio of 
the molecules in EMD. After normalization based on total spot density was performed, 
the relative volume of individual spots was calculated and quantified by the intensity of 
staining. After Western blotting images were also scanned at 500 dpi, the signals on the 




Preparation of recombinant mouse amelogenin 
 
To construct a plasmid expressing amelogenin, cDNA was amplified by PCR. The 
amplified DNA fragment was cloned into the BamHI–XhoI region of pET22b (+) 
(Novagen, Darmstadt, Germany), which allowed the expressed amelogenin protein to 
fuse to the poly–histidine tag at the C–terminus. Recombinant amelogenin (rAMEL) 
was expressed as an insoluble inclusion body in E. coli BL21 harboring the plasmid by 
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treatment with isopropylthio–β–D–thiogalactoside, and was solubilized in 20 mM 
sodium phosphate buffer (NaPB) containing 0.5 M NaCl and 6 M guanidine 
hydrochloride. The solubilized rAMEL was purified by Ni2+–chelate affinity 
chromatography using a ProBondTM resin column (Invitrogen) according to the 
manufacturer’s instructions. Briefly, crude rAMEL was applied to the column and 
eluted with 20 mM NaPB containing 8M urea and 0.1% Triton–X100. The purified 
fractions were dialyzed against 20 mM NaPB (pH 4.0) containing 0.1% Triton–X100 to 
remove the urea. Removal of lipopolysaccharide (LPS) was accomplished by Triton 
X–114 (SIGMA, St. Louis, MO) [17]. The rAMEL used in this study contained less 
than 1 pg of LPS per 1 μg of protein. 
 
 
Cell culture and signaling assay 
 
The mouse osteoblast cell line MC3T3–E1 was obtained from RIKEN Cell Bank 
(Tsukuba, Japan). Cells were maintained in α–MEM (SIGMA) containing 10% fetal 
bovine serum (FBS; Invitrogen) and 100 units/mL of penicillin–G at 37˚C in a 
humidified atmosphere of 5% CO2 in air. Cultured MC3T3–E1 cells were treated with 5 
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μg/mL of EMD, 5 μg/mL of rAMEL and 100 ng/mL of recombinant BMP2 
(Genzyme/Techne, Cambridge, MA) for 0 to 60 minutes. Treated cells were washed 
with phosphate buffered saline (PBS) containing 1 mM Na3VO4, and then solubilized in 
200 μL of lysis buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 10 mM MgCl2, 0.5% 
Nonidet P–40, 1 mM phenylmethylsulfonyl fluoride, 20 units/mL aprotinin). The lysed 
cell solution was centrifuged at 12, 000 x g for 10 minutes and the supernatants 
recovered were used as samples to assay cell signaling. The protein concentration of 
each sample was measured using Lowry’s method. After the samples were separated on 
NuPAGE® 4–12% Bis–Tris gels (Invitrogen), the gels were transferred onto PVDF 
membranes. To assay cell signaling during phosphorylation, the membranes were 
analyzed by Western blotting using anti–phospho ERK1/2 (p–ERK1/2), anti–ERK1/2, 
anti–phospho Smad1/5/8 (p–Smad1/5/8), and Smad5 antibodies (Cell Signaling 
Technology, Beverly, MA)  
 
 
Amino acid sequence of characteristic spots on 2–D gels 
 
Separated EMD samples on 2–D gels were blotted onto PVDF membranes. Then, 
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characteristic spots on the 2–D gels were excised from the blotted membranes and 
subjected to sequencing using a Procise 492cLC (Applied Biosystems, Foster City, 
CA.). Homology searches of the resultant sequences were performed using 
protein–protein BLAST (blastp) located on the web site of the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/).  
 
 
Assay of binding between amelogenin and BMP2 
 
0 to 1.0 μg of rAMEL was dissolved in PBS and added to 100 ng of BMP2 in a final 
volume of 250 μL and incubated at 4˚C for 8 hours. Following incubation, 0.25 μL of 
Ni2+–chelate ProbondTM resin (Invitrogen) was added to the reaction mixture and 
incubated at 4˚C for 8 hours. Resin beads were recovered by centrifugation and washed 
5 times with 1000 μL of PBS. The opposite way for the above reaction was also 
analysed. 100 ng of rAMEL was dissolved in PBS and added to 0 to 500 ng of BMP2 in 
a final volume of 250 μL and incubated at 4˚C for 8 hours. The resulting complexes 
were immunoprecipitated using anti–BMP 2/4 antibody coupled with protein G plus 
protein A agarose (Calbiochem, Darmstadt, Germany) at 4˚C for 1 hour. These 
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precipitates were suspended in NuPAGE® LDS sample buffer and applied to NuPAGE® 
4–12% Bis–Tris gels. The gels were electrophoresed gel and blotted onto PVDF 
membranes, then subjected to immunostaining respectively using the anti–BMP2/4 and 
anti-AMEL antibody, as described above. 
 
 
Analyses of binding affinity of rAMEL for heparin and heparan sulfate 
 
5 μg of rAMEL was mixed with 0 to 200 μg of heparin acrylic beads or 0 to 100 μg 
of heparan sulfate in 500 μL of binding buffer (25 mM Tris–HCl (pH 7.5), 0.1 M NaCl, 
0.1% CHAPS) and incubated at 4ºC for 8 hours. Acrylic beads (200 μg) 
(Sephacryl® 100–HR; SIGMA) were used as a negative control to prevent the binding of 
rAMEL to the beads themselves. Following incubation, the heparin beads were 
recovered by centrifugation and washed 5 times with 200 μL of binding buffer. The 
binding affinity of rAMEL for heparin was detected using Western blotting analyses of 
reaction intensity against the anti–AMEL antibody. For the analysis of the intensity of 
binding of rAMEL to heparin, 0.2 to 1.0 M NaCl was added to the above binding buffer, 
and the intensity was evaluated by the concentration of NaCl when binding. In the 
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binding affinity of rAMEL for heparan sulfate, the free rAMEL, which did not bound to 
heparan sulfate in the rAMEL–heparan sulfate complex mixture, was recovered by 
heparin beads and analyzed by using the same protocol. 
 
 
Assay of alkaline phosphatase activity 
 
MC3T3–E1 cells were cultured in the presence of 50 ng/mL of BMP2 and various 
concentrations of rAMEL with or without 400 ng/mL of noggin (R&D Systems) for 14 
days. Assays of alkaline phosphatase (ALP) activity were performed with a TRACP & 
ALP Assay Kit® (Takara, Tokyo, Japan), according to the manufacturer’s instructions. 
 
 
Inhibition of binding between BMP2 and noggin by rAMEL 
 
rAMEL (0–5 μg) was mixed with 1 μg of BMP2 and 100 ng of noggin in 500 μL of 
binding buffer and incubated at 4˚C for 8 h. The resulting complexes were 
immunoprecipitated using anti–BMP 2/4 antibody coupled with protein G plus protein 
 15
A agarose (Calbiochem, Darmstadt, Germany) at 4˚C for 1 h. The precipitates were 
electrophoresed, transferred to PVDF membranes, and immunoassayed using 





Triplicate samples were analyzed in each experiment, with each replicated to ensure 
consistency of the responses to amelogenin. Significant differences were determined 





EMD contains amelogenin and BMP2/4, but not TGF–β 
 
A previous report found that EMD prepared from developing porcine teeth 
possesses BMP–like and TGF–β–like activities [3, 4], though the molecular mechanism 
is uncertain. To obtain detailed findings regarding the molecules contained in EMD, we 
performed 2–D PAGE analysis of EMD protein using a Zoom IPG Runner System (see 
materials and methods section). 
Primary spots were detected in the area with a molecular weight (MW) ranging from 
3 to 25 kDa and an isoelectric point (pI) ranging from 6.2 to 10 (Fig. 1A). At around 22 
kDa and pI 7.0, a large number of high–density spots were found, which were identified 
as full–length amelogenin by Western blot analysis probed with the rabbit polyclonal 
anti–AMEL antibody (Fig. 1B). In our Western blotting analysis using the goat 
polyclonal anti–BMP2/4 antibody, clearly positive spots were seen in a range of 80 
kDa/pI 7.6–8.2 and 110 kDa/pI 7.2–7.5 (Fig. 1C). Western blot analysis using the 
anti–TGF–β1 was also carried out, however, no detectable protein was observed that 
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interacted with that antibody (data not shown).  
 
 
Amelogenin enhances phosphorylation of ERK, but not Smad, in MC3T3–E1 osteoblasts 
 
Since our results demonstrated that EMD contains BMP proteins, we compared the 
ability to activate cell signaling in MC3T3–E1 osteoblasts among EMD, purified 
rAMEL, and BMP2. The obtained rAMEL at 5 μg/mL induced phosphorylation of 
ERK–1/2 (Fig. 2A), which demonstrated that the rAMEL was physiologically intact. 
Consistent with a previous study of fibroblasts [18], stimulation with 5 μg/mL of EMD 
also induced ERK–1/2 phosphorylation. These results suggest that amelogenin, which 
comprises more than 90% of EMD, is the molecule involved in activation of the ERK 
pathway when osteoblasts are stimulated with EMD. 
On the other hand, the phosphorylation of Smad was observed when BMP2 or EMD 
and not rAMEL was added (Fig. 2B). Therefore, we speculated that the BMP–like 
activity of EMD is not dependent on amelogenin, but rather the BMP protein contained 




Imaging analysis of 2–D PAGE spots and amino acid sequence of two unknown 
fractions 
 
Figure 1D shows results of imaging analysis of 2–D PAGE and Western blotting 
assays. Those results led us to determine the molecules that equalled 19.5% of the total 
that did not interact with the anti–AMEL and anti–BMP2/4 antibodies.  
We attempted to identify the unknown fractions detected as two different spots with 
comparatively intense signals, indicated by arrowheads in Figure 1D. The N–terminal 
20 amino acids sequence of those were revealed to be MPLPPHPGHPGYINFSYEVL 
and MPLPPHPGHPGYINFFYEVL, and showed a similarity to amelogenin in a blastp 
homology search.  
 
 
Amelogenin binds to BMP 
 
Figure 1D revealed that the yellow spots occupied 6.8% of EMD reacted to both 
anti–AMEL and anti–BMP2/4 antibodies. Thus, we speculated that amelogenin possess 
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the binding activity to BMP. To confirm this finding, we examined the interaction of 
amelogenin and BMP2 in vitro using a protein binding assay (Fig. 3). Poly–histidine 
tagged rAMEL was incubated with Ni–beads and BMP2 prepared from CHO cells. The 
mixture of rAMEL and Ni–beads was negative in subsequent immunoblot analysis 
using anti–BMP2/4 antibody. With regard to the mixture of rAMEL, BMP2, and 
Ni–beads, a positive band against the anti–BMP2/4 antibody was observed when more 
than 0.5 μg of rAMEL was added, and the intensity of the band increased in a 
concentration–dependent manner (Fig. 3A). Then, the binding activity between rAMEL 
and BMP2 was also observed in the opposite way for the above (Fig. 3B). As the result, 
it was developed that the binding intensity increased just like the above mentioned. 
From these results, the interaction between amelogenin and BMP2 was confirmed. 
 
 
Amelogenin binds to heparin/heparan sulfate 
 
It is well known that both growth factors such as BMP2/4 and extracellular matrix 
to interact with heparin/heparan sulfate [19, 20]. Since the molecular weight of the 
amelogenin–BMP merged spots was greater than the sum of each individually and, we 
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speculated that heparan sulfate was involved in amelogenin–BMP molecular 
interactions.  
First, to confirm the binding of amelogenin and heparin, we precipitated rAMEL 
with heparin beads. The precipitation of rAMEL by the heparin beads occurred in a 
concentration–dependent manner; however, this was not observed in the case of rAMEL 
precipitation by the acrylic beads (Fig. 4A). In the examination of the avidity between 
rAMEL and heparin, the addition of more than 0.9 M NaCl decreased binding activity 
(Fig. 4B). These results suggest that amelogenin binds to heparin in vivo. The complex 
of rAMEL and heparin was competitively decreased by the addition of heparan sulfate 
(Fig. 4C). Thus, it was demonstrated that rAMEL binds to not only the heparin but also 
the heparan sulfate.  
 
 
Amelogenin promotes BMP function following noggin suppression 
 
When it was based on the hypothesis that amelogenin possess the binding activity to 
BMP, it was interesting whether amelogenin act as agonist or antagonist on the ALP 
activity associated with BMP. As shown in Figure 5A, the addition of rAMEL did not 
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inhibit up–regulation of ALP activity in MC3T3–E1 cell by BMP2. On the other hand, it 
was reported that the addition of noggin inhibited acceleration of ALP activity by BMP2 
as reported formerly [21]. When examining the effect of amelogenin on this inhibition 
by noggin, a low concentration of rAMEL did not depress the effect of noggin. However, 
the ALP activity associated with BMP was recovered by adding more than 10 μg/mL of 
rAMEL (Fig. 5B). 
 
 
Amelogenin inhibits binding of noggin to BMP2 
 
Based on the observation that rAMEL repressed the inhibition of BMP–associated 
ALP activity by noggin (Figure 5B), it was speculated that amelogenin inhibited the 
binding between BMP2 and noggin. Thus, we investigated whether rAMEL inhibited 
the binding between BMP2 and noggin by immunoprecipitation. It was found that 
rAMEL inhibited the binding between BMP2 and noggin when it was added at a 
concentration that was 10–fold greater than that of noggin (Fig. 6). This ratio between 





All splicing forms, such as tyrosine–rich amelogenin (TRAP) and leucine–rich 
amelogenin (LRAP), have different functions and are expressed in various tissues [22, 
23]. In the present study, CBB staining indicated that EMD could be separated into 46 
proteins, and spots that reacted with the anti–AMEL antibody were observed in a MW 
range from 8 to 24 kDa and a pI range from 7.2 to 9.3 (Fig. 1B). These results 
confirmed those of the previous report about the component of EMD using anti-AMEL 
antibody, which revealed that EMD was composed mainly of amelogenin and that EMD 
contains many splicing form of amelogenin raging 10 to 40 kDa with the majority 
components at 20 kDa [24]. In this report, the western blotting analyses of EMD using 
anti-amelin, anti-enamelin, and anti-albumin antibodies were also carried out and 
revealed that no cross-reactivity was seen. However, although EMD has BMP and 
TGF-β activity [3, 4], there is no report concerning the western blotting analyses of 
EMD using anti-BMP and anti-TGF-β antibodies. Thus, we performed the immunoblot 
analyses using these antibodies. 
Immunoblot analysis showed that EMD derived from porcine samples did not react 
 23
with the anti–human TGF–β1 antibody (data not shown). According to the 
manufacturer’s instructions, the anti–human TGF–β1 antibody used in this study reacts 
with TGF–β1 derived from humans, rats, and mice. The amino acid sequence homology 
between porcine TGF–β1 and that of those is 94%, 89%, and 89%, respectively. In a 
phylogenetic tree from those animal species based on the neighbor–joining method, 
porcine TGF–β1 is located between that of humans and rodents, and belongs to the 
same cluster as human TGF–β1 (data not shown). Therefore, the possibility that porcine 
TGF–β1 does not react with the tested anti–TGF–β1 antibody is very low. Thus, it is 
suggested that TGF–β1 is not involved with EMD and that amelogenin or other 
molecules in EMD may possess TGF–β–like activities. 
Positive fractions were detected in our Western blot analysis of EMD with the 
anti–BMP2/4 antibody (Fig. 1C). Expression of BMP was reported to be shifted 
between epithelium and mesenchyme during the tooth initiation stage, and remarkable 
associations with epithelial–mesenchymal interactions were shown [25]. In addition, we 
confirmed that amelogenin binds to BMP2 (Fig. 3). Thus, it is suggested that the 
BMP–like molecule is retained during the purification process of EMD due to this 
binding ability of amelogenin. 
BMP2/4 induce differentiation of osteoblasts [26] and belong to the TGF–β family 
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of proteins that act as potent osteogenic morphogens capable of inducing calcification in 
animal models [27]. Thus, we examined the effects of EMD and single rAMEL on the 
Smad phosphorylation induced by BMP2, which was an important signaling pathway in 
calcification. We found that the phosphorylation of Smad 1/5/8 was not induced by 
amelogenin alone, but rather by whole EMD (Fig. 2C), indicating that amelogenin does 
not inhibit BMP signaling. Thus, it was suggested that the BMP–like molecule in EMD, 
which might be the precursor of BMP at its molecular weight, induced the 
phosphorylation of Smad. It was reported that bone inducing activity was displayed by 
proBMP2 [28]. Therefore, it is suggested that EMD extracted from porcine tooth germ 
tissue has a pharmacological effect on bone formation and periodontal reproduction, 
based on its contamination with trace amounts of active BMP. 
Heparin/heparan sulfate binds to growth factors, including BMP, the fibroblast 
growth factor (FGF) family, heparin–binding epidermal growth factor, and vascular 
endothelial growth factor [19, 29–31], as well as to extracellular matrix molecules such 
as fibronectin, vitronectin, and laminin [20]. Proteoglycans have been identified within 
bone extracellular matrices and are known to play a role in mineralization and bone 
formation. BMP2–induced osteoblasts induce the synthesis of secreted 
chondroitin/dermatan sulfate proteoglycans and heparan sulfate proteoglycans 
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associated with the cell and its environment [32]. Heparin enhances BMP2–induced 
gene expression and Smad1/5/8 phosphorylation. Noggin failed to inhibit BMP2 
activity in the presence of heparin [33]. Sulfated polysaccharides enhance the biological 
activity of BMP dimers by continuous delivery of the ligands to their signaling receptors 
expressed on cell membranes [34]. Based on those results, we speculated that 
amelogenin, an extracellular matrix molecule, would bind to heparin/heparan sulfate, 
which was confirmed in the present experiments (Fig. 4A). It has also been reported that 
FGF binding to heparin was abrogated by 0.5 to 0.9 M NaCl [35, 36] and amelogenin 
binding to heparin was dissociated in 0.9 M NaCl in the present study (Fig. 4B). Thus, it 
was revealed that the avidity between amelogenin and heparin is the same as that 
between FGF and heparin. Further, we found that amelogenin binds to not only heparin, 
but also heparan sulfate (Fig. 4C). These results suggest that amelogenin contributes to 
bone formation via binding to heparan sulfate. 
It was previously reported that BMP2 can bind to other molecules such as noggin, 
chordin, follistatin, and biglycan [37–40]. It was also reported that noggin has an ability 
to bind to heparan sulfate and functions as an antagonist of BMP [21, 41]. On the other 
hand, the present results indicate that amelogenin possesses the ability to bind to both 
BMP2 and heparan sulfate. However, the influence of amelogenin on calcification by 
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BMP has not been reported. Thus, amelogenin was added to the present experimental 
system, in which the up–regulation of alkaline phosphatase activity by BMP was 
inhibited by noggin, and high density amelogenin rescued the inhibited calcification 
(Fig. 5). The result in Figure 6 indicates that amelogenin inhibited binding of noggin to 
BMP2 and that BMP2 become functionally free. These results suggest that a high 
concentration of amelogenin may be effective for use as a therapeutic agent for 
promoting bone formation, though such concentrations do not exist in vivo. 
In conclusion, our findings indicate that the BMP–like activity of EMD is derived 
from trace amounts of BMP2/4 carried over during the production process, and caused 
by the ability of amelogenin to bind to BMP. Moreover, since amelogenin suppressed 
the inhibition of the BMP–induced ALP activity by noggin, amelogenin may be 
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Fig. 1. Two dimensional electrophoresis analysis of EMD. CBB staining of EMD 
separated on 2–D PAGE gel (A). The gel was transferred to a PVDF membrane and 
immunostained with anti–AMEL (B) and anti–BMP2/4 (C) antibodies. The images 
were matched using Progenesis PG200 software. Merged image (D) shows BMP2/4 
(red) and amelogenin (green), with overlapping regions shown in yellow. 
 
Fig. 2. Effects of EMD, amelogenin, and BMP2 on intracellular signaling pathways in 
osteoblasts. MC3T3–E1 cells were cultured in the presence of either EMD, rAMEL, or 
BMP2 for 0–60 minutes. Proteins in the cells were immunostained with anti–phospho 
ERK1/2 (p–ERK1/2) and anti–ERK1/2 antibodies (A), or anti–phosphor Smad1/5/8 
(p–Smad1/5/8) and anti–Smad5 antibodies (B). 
 
Fig. 3. Binding activities of amelogenin to BMP2. The complexes comprising 0 to 1.0 
μg of rAMEL and 100 ng of BMP2 were affinity-precipitated (AP) by Ni-beads (A). 
The complexes comprising 100 ng of rAMEL and 0 to 500 ng of BMP2 were 
immunoprecipitated (IP) by anti-BMP2/4 antibody coupled with protein G plus protein 
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A agarose (B). After washing with buffer, each recovered bead was electrophoresed, 
transferred and immunostained with anti–BMP2/4 and Anti-AMEL antibody, 
respectively. 
 
Fig. 4. Avidity analyses of amelogenin and heparin/heparan sulfate. The avidity of 
amelogenin and heparin/heparan sulfate was analyzed by examining the binding of 
rAMEL to heparin beads by performing Western blotting using the anti–rAMEL 
antibody. The binding affinity of rAMEL for heparin was detected by the incubation of 
rAMEL with 0–200 μg of heparin acrylic beads (A). The binding intensity between 
rAMEL and heparin was evaluated by estimating the concentration of the NaCl buffer 
during the binding (B) (*p < 0.001). The binding affinity of rAMEL for heparan sulfate 
was determined by estimating the amounts of free rAMEL in the rAMEL–heparan 
sulfate complex mixture (C). 
 
Fig. 5. Influence of amelogenin on the inhibition of the BMP2–induced alkaline 
phosphatase activities by noggin. MC3T3–E1 cells were cultured in 50 ng/mL BMP2 
and/or 0–20 ng/mL rAMEL without noggin (A) or with 400 ng/mL noggin (B). After 14 
days, the cells were histochemically stained for ALP activity (*p<0.001). 
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Fig. 6. Effect of amelogenin on the binding between BMP2 and noggin. The mixture of 
rAMEL, BMP2, and noggin was immunoprecipitated (IP) with the anti–BMP2/4 
antibody coupled with protein G plus protein A agarose, and the recovered precipitate 
was analyzed by Western blot performed with the anti–noggin antibody. 
 
Supplementary figure 1. 2–D PAGE profile of EMD derived from porcine. EMD 
separated on 2–D PAGE gel was stained with CBB and the fractions were numbered (A). 
Based on the results of CBB staining and Western blotting, the pI, molecular weight, 
and relative volume of each fraction were calculated by Progenesis PG200 Software 
(B).  
 
Supplementary figure 2. The electric pattern of EMD was changed by the different 
reducing condition or by the digestion of furin. The EMD samples were reduced in 
different condition or treated with furin, by which pro-BMP was cleaved. The lane 1 
was reduced in the manufacturer’s recommended condition by the addition of 50 mM 
DTT and the incubation at 70°C for 10minutes. The lane 2 was reduced in the strict 
condition by the addition of 150 mM DTT and the incubation at 95°C for 15 minutes. 
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The lane 3 was digested by furin at 37°C for 8 hours and reduced in the strict condition. 
The lane M is the molecular weight marker. These were electrophoresed and 
immunologically analyzed. The gel on which the lane 1 and 2 were electrophoresed was 
stained by CBB (A). The EMD samples reduced in the different reducing condition 
were immunostained with anti-AMEL antibody (B). The EMD samples reduced in the 
different reducing condition and digested by furin were immunostained with 
anti-BMP2/4 antibody (C). In the panel A, since the approximate 60 kDa band appeared 
in the lane 2 instead of disappearance of the 80 and 110 kDa bands in the lane 1, it was 
suggested that the manufacturer’s recommended condition was insufficient in the 
reducing of EMD. In the panel B, the 80 kDa band immunostained with anti-AMEL 
antibody in the lane 1 disappeared in the lane2. This observation indicated that the high 
molecular weight fraction immunostained with anti-AMEL and anti-BMP-2/4 antibody 
in Figure 1D would be reduced in the strict condition. In the panel C, the approximate 
60 kDa band immunostained with anti-BMP-2/4 antibody appeared in the lane2 instead 
of disappearance of the 80 and 110 kDa bands in the lane 1. Then, the approximate 60 
and 18 kDa bands were detected with anti-BMP-2/4 antibody in the lane3. Thus, it was 
developed that the anti-BMP2/4 antibody positive fraction in EMD shifted from 80 and 
110 kDa to approximate 60 kDa by the strict reducing condition and that the 60 kDa of 
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the anti-BMP2/4 antibody positive band corresponding to the pro-BMP was digested 
into the approximate 18 kDa band corresponding to the processed BMP. 
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